46th week of 2010 patent applcation highlights part 34 |
Patent application number | Title | Published |
20100290980 | FLUORINE EXTRACTION SYSTEMS AND ASSOCIATED PROCESSES - Fluorine extraction systems and associated processes are described herein. In one embodiment, a fluorine extraction process can include loading a mixture containing a uranium fluoride (U | 2010-11-18 |
20100290981 | MONOLITHIC CATALYST AND USES THEREOF - A monolithic and non-supported catalyst composition for use in a variety of chemical transformations is provided. Further provided is a process for the catalytic transformation of an organic compound, as well as a process for the catalytic decomposition of a hydrocarbon. | 2010-11-18 |
20100290982 | SOLID IN OIL/WATER EMULSION-DIFFUSION-EVAPORATION FORMULATION FOR PREPARING CURCUMIN-LOADED PLGA NANOPARTICLES - The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoparticle, wherein an active agent is encapsulated in or about the nanoparticle. | 2010-11-18 |
20100290983 | Compositions and Methods for Drug Delivery - The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises a surfactant having formula I, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm: | 2010-11-18 |
20100290984 | ANTI-MRP3 ANTIBODIES AND METHODS OF USE - An antibody having an antigen binding region capable of binding an epitope located in an extracellular portion of MRP3 and methods of utilizing same are provided. In particular, the invention provides antibodies targeted at a MRP3 antigen present on cells expressing MRP3 and methods useful in detecting or targeting cells expression the MRP3 antigen, as well as kits, nucleic acids, polypeptides, and cells for providing the antibodies. | 2010-11-18 |
20100290985 | MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF - The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease. | 2010-11-18 |
20100290986 | THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES - The present invention relates generally to methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimised pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects. | 2010-11-18 |
20100290987 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING O-GLYCOSYLATION - The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention is also useful for identifying therapeutic compounds to treat de-glycosylation-associated disorders such as ischemic damage and traumatic injury. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins and also relates in part to compounds to treat glycosylation-associated diseases and disorders. | 2010-11-18 |
20100290988 | FLUORINATED FRUCTOSE DERIVATIVES FOR PET IMAGING - The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies. | 2010-11-18 |
20100290989 | COMPOSITIONS AFFECTING HYALURONIC ACID MEDIATED ACTIVITY - Compositions comprising hyaluronic acid (HA) or agents that interfere with HA binding of HA receptors and methods of using the same are provided. For example, there is provided a composition comprising HA oligomers ranging in size from 10-mer to 80-mer and use of the same for promoting migration, growth or survival of wild-type or transformed/cancerous cells. There is also provided a composition comprising an agent that interferes with binding between an HA oligomer of a size of about 10-mer to about 80-mer and an HA receptor. Such compositions may be useful for therapeutic, diagnostic or imaging applications. Examples of therapeutic use are wound repair or cancer treatment. | 2010-11-18 |
20100290990 | METHOD FOR PREPARING A MARKED PURINE DERIVATIVE, SAID DERIVATIVE AND USES THEREOF - The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope | 2010-11-18 |
20100290991 | NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION - What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use. | 2010-11-18 |
20100290992 | NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS - The present invention concerns the field of nanoparticle bioconjugates which form an i-motif or an i-motif related structure (compositions) without or with at least one further nucleic acid binding compound. The i-motif base pairs can be charged or non-charged. Their assembly can be controlled by the pH value or temperature. At least one of these nucleic acid binding compounds has to be attached at least to a nanoparticle. The methods provide compositions used for DNA driven programmable nanoparticle assemblies, electronic circuits, diagnostic detection tools, biosensors, memory storage devices, diagnostic devices for biomolecule sequencing and detection, drug delivery, application in tumour diagnostics and treatment, nanomachines, nanofabrication, nanocatalysis, nanoarrays, and nanoscaled enzyme reactors. | 2010-11-18 |
20100290993 | Antibodies to IL-6 and use thereof - The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2010-11-18 |
20100290994 | O-Methylated Rapamycin Derivatives For Alleviation And Inhibition Of Lymphoproliferative Disorders - The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal. | 2010-11-18 |
20100290995 | RADIO-OPAQUE COMPOUNDS, COMPOSITIONS CONTAINING SAME AND METHODS OF THEIR SYNTHESIS AND USE - Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts. | 2010-11-18 |
20100290996 | METHODS AND COMPOSITIONS BASED ON CULTURING MICROORGANISMS IN LOW SEDIMENTAL FLUID SHEAR CONDITIONS - This invention is directed to applying a low sedimental fluid shear environment to manipulate microorganisms, and to microorganisms and compositions obtained based on such manipulation. Specifically, the present invention provides methods of modifying a molecular genetic or phenotypic characteristic (e.g., virulence, stress resistance or biofilm formation) of a microorganism by culturing in a low sedimental shear environment. One or more ion concentrations in the culture can be modulated in order to inhibit or amplify the extent of the modification. The present invention also provides microorganisms obtained from a low sedimental shear culture, which exhibit modified and desirable phenotypic characteristics, as well as therapeutic, vaccine and bioindustrial products prepared from such microorganisms. Further, the present invention provides methods for identifying molecules that modulate responses of a microorganism to a low sedimental shear environment and for determining the relevance of such molecules to pathogenenicity of the microorganism. | 2010-11-18 |
20100290997 | Imaging Agents and Methods - The disclosure includes a composition including a poly(L-glutamic acid) and a NIRF dye. It also includes a method including providing to a plurality of cells an imaging agent including poly(L-glutamic acid), a NIRF dye and then imaging the cells to detect the imaging agent. It further includes a dual functional contrast agent including an MRI agent conjugated with an optical imaging agent. A method of detecting cancer is provided including injecting a dual functional contrast agent into a patient and performing both an MRI and an optical scan. The presence of the agent may indicate cancer. A method of detecting cancer by injecting PG-DTPA-Gd-NIR813 into a patient, then detecting the presence or absence of Gd in a cell or tissue of the patient and detecting the presence or absence of NIR813 in a cell or tissue of the patient is provided. The presence of Gd and NIR813 may indicate cancer. | 2010-11-18 |
20100290998 | Methods of preventing ischemic injury using peripheral nociceptive stimulation - Methods of inhibiting ischemia-related and ischemia-reperfusion-related injury are provided. Remote administration of a C-fiber activator or TRPV1 agonist or remote electrical stimulation and activation of TRPV1 reduces ischemia-related tissue damage in subjects at risk for ischemia-related tissue damage. In aspects of the invention, remote application of a TRPV1 agonist inhibits ischemia-related cardiac tissue damage. Methods of inhibiting cardiac tissue damage by topically administering the TRPV1 agonist, capsaicin are provided. | 2010-11-18 |
20100290999 | NANOPARTICLES OF LIGHT EMISSIVE POLYMERS AND PREPARATION METHOD THEREOF - Disclosed are nanoparticles of a light emissive polymer, comprising nanoparticles of a cyano-substituted poly(arylene vinylene) polymer; and a biocompatible surfactant adsorbed to the surface of the nanoparticles of the polymer, and preparation method thereof, wherein the method comprises: (1) uniformly mixing a dialdehyde monomer represented by a general formula OHC—Ar | 2010-11-18 |
20100291000 | Diagnostic value of systemic ACE pathway activation in the detection by fluorescence of localized pathological lesions - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. Once partially activated, ACE pigments within a localized lesion will fluoresce upon direct exposure to UV light. It is diagnostically useful to screen an individual or animal undergoing localized or systemic activation of their ACE pathway for the presence of lesions elsewhere in the body, which become fluorescent under direct UV illumination, both as a way of detecting an otherwise non-apparent or unnoticed lesion and of confirming that such a lesion contains ACE pigments that can be further activated. The development of direct UV fluorescence in a localized lesion can also be an indication of the therapeutic value of continuing with direct UV illumination of the lesion. | 2010-11-18 |
20100291001 | METALLOPROTEINASE-BINDING PROTEINS - Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders. | 2010-11-18 |
20100291002 | COMBINATION COMPRISING PYRROLIDONE-5-CARBOXYLIC ACID AND AT LEAST ONE COMPOUND FROM CITRULLINE, ARGININE AND ASPARAGINE, AND USE THEREOF IN THE TREATMENT OF ATOPIC DERMATITIS - Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis. | 2010-11-18 |
20100291003 | HISTONE DEACETYLASE INHIBITORS - Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I). | 2010-11-18 |
20100291004 | COMPOSITIONS FOR DELIVERING HYPNOTIC AGENTS ACROSS THE ORAL MUCOSA AND METHODS OF USE THEREOF - The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided. | 2010-11-18 |
20100291005 | USE OF TRANS-PELLITORIN AS FLAVOR SUBSTANCE - The invention concerns the use of 2E,4E-decadienoic acid-N-isobutylamide (trans-pellitorin) as flavorant, in particular as salivation inducing flavor substance, preferably in a foodstuff or nutrient, an oral hygienic preparation or a gourmet or snack preparation. Further, the invention concerns preparations, semi-finished preparations as well as fragrance, aroma and taste compositions, containing trans-pelletorin as well as a processes for the production of trans-pelletorin. | 2010-11-18 |
20100291006 | Natural Preservatives and Antimicrobial Agents - The invention relates to preservatives and antimicrobial agents including extracts derived from sugar cane. | 2010-11-18 |
20100291007 | Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase - The present invention relates to the cosmetic or pharmaceutical use of an extract of a nonfruiting nonphotosynthetic filamentous bacterium in a composition containing a cosmetically or pharmaceutically acceptable medium, as an agent increasing the endogenous synthesis of superoxide dismutase, in particular for preventing and/or limiting the formation of free radicals and/or removing the free radicals present in cells; in addition, the invention relates to a composition comprising at least one extract of | 2010-11-18 |
20100291008 | EMULSION COMPOSITION - An emulsion composition includes a UV scattering agent and at least one of an active oxygen remover or an anti-oxidizing agent. The UV scattering agent is added to one of an oil phase or an aqueous phase of the emulsion composition and the at least one of an active oxygen remover or an anti-oxidizing agent is added to the other of the oil phase or the aqueous phase. | 2010-11-18 |
20100291009 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES - The invention relates to preparations comprising at least one compound of the formula (I), where the substituents R | 2010-11-18 |
20100291010 | NOVEL ESTERS AND COMPOSITIONS AND USES THEREOF - A novel ester of an optionally substituted aromatic acid (for example benzoic acid) and a branched C | 2010-11-18 |
20100291011 | Water-In-Oil Emulsion Type Sunscreen Cosmetic - A water-in-oil emulsified sunscreen cosmetic comprising (a) 0.1-10 wt % of dimethicodiethylbenzalmalonate, (b) 0.02-8 wt % of phenylbenzimidazole sulfonic acid, and (c) a neutralizing agent for said ingredient (b), said cosmetic having a water phase content of 40 wt % or less. | 2010-11-18 |
20100291012 | ADMINISTRATION OF AMOROLFINE BY IONTOPHORESIS FOR TREATING NAIL DISEASES - A regime or regimen for the treatment of a nail disease state includes topically applying onto the infected nail(s) of an individual a thus effective amount of a solution of amorolfine in ionized form and concomitantly applying thereto an iontophoretic current of such intensity as to deliver the amorolfine into and/or through the infected nail(s). | 2010-11-18 |
20100291013 | COMFORTABLE, TRANSFER-RESISTANT COLORED COMPOSITIONS - A composition for application to the skin includes (a) at least one film forming resin chosen from a polypropylsilsesquioxane wax substituted with alkyl units having at least 30 carbon atoms; (b) at least one volatile solvent capable of solubilizing (a); (c) at least one gelling agent chosen from a modified clay; and (d) a structuring agent, wherein the composition has a hardness value ranging from about 85 g to about 145 g. | 2010-11-18 |
20100291014 | Pigment Mixtures - Disclosed are pigment mixtures containing at least two components, where component A contains bismuth oxychloride (BiOCl) or boron nitride (BN) and component B contains synthetic flakes treated with at least one metal soap or mineral flakes treated with at least one metal soap and to the use thereof especially in cosmetic formulations. | 2010-11-18 |
20100291015 | METHOD FOR MAKING UP THE LIPS - The invention relates to a method for making up the lips comprising the steps of selecting at least one composition, referred to as ‘first composition’, from a range of first compositions formulated in the liquid state, of selecting at least one composition, referred to as ‘second composition’, from a range of second compositions distinct from the range of first compositions, of mixing the first and second compositions at ambient temperature and of applying said mixture to the lips. | 2010-11-18 |
20100291016 | PERFUMING INGREDIENTS IMPARTING SAP AND/OR EARTHY TYPE NOTES - The present invention relates to the field of perfumery. More particularly, it concerns specific derivatives of 1-alkenyl cyclopentanol, or 1-alkenyl cyclohexanol, wherein the alkenyle group is branched. These compounds are useful perfuming ingredients capable of imparting sap and/or earthy notes. | 2010-11-18 |
20100291017 | Hair Treatment Compositions - The invention provides a hair treatment composition comprising a combination of a sugar, an amino acid and a salt of an organic acid. The composition is particularly suitable for the treatment of hair which is dry, damaged and/or prone to manageability problems. | 2010-11-18 |
20100291018 | CONDITIONER FOR EYELASH AND EYEBROW - A conditioner for eyelash and eyebrow includes: water; hydrolyzed soy protein; erythritol; trehalose; carbomer; arginine; polysorbate 80; niacinamide; panthenol; citric acid; phenoxyethanol; acorus calamus root extract; artemisia princes leaf extract; portulaca oleracea extract; polygonum multiflorum root extract; glycyrrhiza glabra root extract; ephedra sinica extract; sophora angustifolia root extract; arctium lappa seed extract; thuja extract; lyceum barbarum fruit extract; ginko biloba leaf extract; paeonia suffruticosa root extract; carthamus tinctorius flower extract; bletilla strita root extract; rheum undulatum root-stalk-stern extract; biotin; methylparaben; and copper tripeptide-1. | 2010-11-18 |
20100291019 | Methods of Using Ophthalmic Compositions Comprising Povidone-Iodine - A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient. | 2010-11-18 |
20100291020 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS - The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved. | 2010-11-18 |
20100291021 | ALIPHATIC PRODRUG LINKER - A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety—such as a drug—can be released by cleaving the temporary linkage. | 2010-11-18 |
20100291022 | Fly Gel Bait - The invention relates to baits for controlling flies (fly gels) comprising a) one or more neonicotinoids, b) one or more gelling agents, c) one or more attractants, and having a gel point between having a Brookfield yield value between 150 and 1000 and a Brookfield viscosity between 40,000 and 150,000 mPa.s, to a process for the preparation of such fly gels, its use and methods for controlling flies. | 2010-11-18 |
20100291023 | METHOD FOR EXTENDING THE HALF-LIFE OF EXOGENOUS OR ENDOGENOUS SOLUBLE MOLECULES - The present invention relates to methods for extending the in vivo half-life of an exogenous soluble therapeutic molecule administered to a subject, by administering to said subject the exogenous soluble molecule and a monovalent antibody that binds to the exogenous soluble molecule, as well as method for treating a disease or disorder associated with an insufficient level of an endogenous soluble molecule in a subject, by administering to said subject a monovalent antibody that binds to the endogenous soluble molecule. | 2010-11-18 |
20100291024 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE AND PATHOGENIC DISEASES - The invention features peptide fragments containing domain 4 of the | 2010-11-18 |
20100291025 | INDAZOLE INHIBITORS OF TYROSINE KINASE - The present invention relates to new indazole inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-11-18 |
20100291026 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 - The present invention relates to new piperidine inhibitors of Janus kinase 3 activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-11-18 |
20100291027 | HYALURONIC ACID (HA) INJECTION VEHICLE - Disclosed herein are compositions that exhibit viscosities suitable for injectable formulations. The compositions comprise bioactive agent-loaded microparticles and hyaluronic acid or a salt thereof in a suitable liquid pharmaceutical carrier. Also disclosed are methods of making and using the compositions. | 2010-11-18 |
20100291028 | USE OF IL-18 INHIBITORS FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL VASCULAR DISEASES - The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation. | 2010-11-18 |
20100291029 | METHODS OF USING IL-21 - An allelic variation in the IL-21 receptor can result in reduced IFN-γ production in individuals and can require administration of different doses of IL-21 to achieve therapeutic effects seen individuals that do not have the allelic variant. Based on the genotype of a patient's IL-21 receptor allele, methods of predicting therapeutic response to treatment with IL-21 are disclosed. Also disclosed are methods of selecting a therapeutic regimen for use of IL-21 in patients with variant IL-21 receptor alleles. | 2010-11-18 |
20100291030 | USE OF IL-28 AND IL-29 TO TREAT CANCER AND AUTOIMMUNE DISORDERS - Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics. | 2010-11-18 |
20100291031 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections. | 2010-11-18 |
20100291032 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION - Methods of identifying inhibitors of retroviral propagation, tRNA used in the methods, and kits, including the tRNA, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed. The methods involve forming a mixture comprising a linear sequence of a tRNA anticodon stem loop fragment that is not capable of forming a stem-loop, a target nucleic acid molecule capable of binding to the tRNA anticodon stem loop fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule. | 2010-11-18 |
20100291033 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2010-11-18 |
20100291034 | COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO - Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations comprising, separately or together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for concurrent or consecutive administration in treating a human subject infected with HCV. | 2010-11-18 |
20100291035 | Respiratory syncytial virus with a genomic deficiency complemented in trans - The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans. | 2010-11-18 |
20100291036 | COMPOSITIONS AND METHODS FOR MODULATING VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION - The present invention relates to compounds and methods for inhibiting the expression of vascular endothelial growth factor-C (VEGF-C) in a target cell. Particularly, the present invention relates to antisense polynucleotides complementary to a lens epithelium-derived growth factor (LEDGF/p75) mRNA and uses thereof for inhibiting tumor progression and tumor metastasis. The present invention further relates to uses of LEDGF/p75 polypeptide or a nucleic acid encoding same for treating endothelial cell related conditions, particularly inflammation and edema. | 2010-11-18 |
20100291037 | IMMUNOGENICITY USING A COMBINATION OF DNA AND VACCINIA VIRUS VECTOR VACCINES - This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC. | 2010-11-18 |
20100291038 | Novel Medicinal Formulation for Inducing an Immune Response in Patients with Chronic and Recurring Infections - A composition for the treatment of respiratory tract infection (RTI) comprising, a homogenized mixture of at least two serially diluted and potentized substances, as herein described, selected from: 1. | 2010-11-18 |
20100291039 | NOVEL MICRO-ORGANISMS CONTROLLING PLANT PATHOGENS - The invention relates to control of pathogen caused diseases on leaves, fruits and ears in plants, such as apple scab ( | 2010-11-18 |
20100291040 | VIRUS-LIKE PARTICLES FOR TREATMENT OF VIRAL INFECTIONS - The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus. | 2010-11-18 |
20100291041 | BACTERIOPHAGE PREPARATION AND USE - The invention relates to a bacteriophage preparation having at least one bacteriophage in alkaline buffer solution, said bacteriophage being specifically effective against at least one bacterial strain, in combination with at least one surface-active agent that is preferably a polyhexamethyl biguanide (polyhexanide) stabilized in an alkaline range between pH 7.5 and pH 9.0. The invention further relates to the use of such a bacteriophage preparation for the production of a pharmaceutical, particularly for therapeutic, preventative, and disinfecting antibacterial use. Finally, the invention also relates to a disinfection method using the bacteriophage preparation together with low-frequency ultrasound. | 2010-11-18 |
20100291042 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided. | 2010-11-18 |
20100291043 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 2010-11-18 |
20100291044 | Lunasin-induced regulation of disease-related gene expression - Methods are provided for screening a test compound for anti-neoplastic activity by providing a test compound to a cancer cell and measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4. Methods are also provided for using a test compound for staging a cancer tissue and for measuring the degree of the test compound's anti-neoplastic activity upon a cancer tissue by providing a test compound to a cancer tissue sample and measuring the degree of methylation of nucleotides within the 5′ region in the cancer tissue sample. | 2010-11-18 |
20100291045 | DYNAMIC VIBRATIONAL METHOD AND DEVICE FOR VOCAL FOLD TISSUE GROWTH - Dynamic vibrational methods and devices for inducing differentiation of stem cells into vocal fold fibroblast-like cells or for generating vocal fold-like tissue from cultured cells. Also provided are matrices providing sustained release of growth factors, and bioreactors generating and delivering a high frequency vibration with in-plane shear stress to cultured cells. | 2010-11-18 |
20100291046 | Equine Progenitor Cells - An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian cartilage damage using such progenitor cells or progeny. | 2010-11-18 |
20100291047 | Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 2010-11-18 |
20100291048 | Modification of CXCR4 using engineered zinc finger proteins - Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided. | 2010-11-18 |
20100291049 | ANTI-WRINKLE AGENT - The invention provides an anti-wrinkle agent which has an excellent effect of inhibiting the formation of wrinkles and excellent safeness. | 2010-11-18 |
20100291050 | Nutritional Compositions for Reducing Oxidative Damage - A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens comprising astragalus root, ashwagandha root, cordyceps, holy basil leaf, maca root, reishi mushrooms, schizandra, and suma root; superfoods comprising acerola, camu-camu, pomegranate, bilberry, blueberry, Goji berries, Acai, maitake, citrus bioflavonoids, rose hips, and Gingko biloba; probiotics comprising bifidobacterium longum, lactobacillus acidophilus, lactobacillus acidophilus DDS-1, lactobacillus bulgaricus, lactobacillus casei, and streptococcus thermophilus; and enzymes comprising amylase, papain, cellulose, lactase, lipase, protease, and bromelain. The nutritional compositions may also be provided as a meal replacement and further comprise one or more plant products, algae, vitamins, minerals, protein and MSM. | 2010-11-18 |
20100291051 | AGENT FOR PREVENTION OF ALCOHOLIC HEPATOPATHY - The present invention provides an agent for inhibition of alcoholic hepatopathy comprising cells of a strain belonging to Lactobacillus brevis, or treated product thereof as an active ingredient. The agent for inhibition of alcoholic hepatopathy of the present invention is safe for living body and can be used as a component in foods and beverages. | 2010-11-18 |
20100291052 | Novel Microorganism Having Gastric-Juice Promoting Activity, and Its Secretory Product - Designed to afford a novel microorganism promoting gastric juice secretion and having platelet increasing activity, and to afford a pharmaceutical agent composed of a product secreted by the novel microorganism. The novel microorganism, international deposit number: NITE BP-295, belongs to the species | 2010-11-18 |
20100291053 | Inflammatory Disease Treatment - We describe a composition comprising a source of long chain polyunsaturated fatty acid, for example, docosahexaenoic acid (DHA), and a carotenoid, for example, astaxanthin and other nutrients for prophylactic and/or therapeutic use in the healing of trauma- and stress-induced inflammatory conditions. | 2010-11-18 |
20100291054 | NOVEL REGULATORY T CELLS AND USES THEREOF - The invention provides isolated regulatory T cells and methods of obtaining regulatory T cells. The invention also provides methods for inhibiting an antigen-specific immune response (e.g., graft rejection, an autoimmune disorder, graft versus host disease, a response to a tumor cell, a response to an infection, and a response to an allergen) in a subject requiring administering an isolated regulatory T cell to the subject. The invention further provides methods for treating or modulating an antigen-specific immune response in a subject requiring administering a regulatory T cell to the subject. | 2010-11-18 |
20100291055 | SURGICAL HYDROGEL - The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined. | 2010-11-18 |
20100291056 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same - The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same. | 2010-11-18 |
20100291057 | Composition for Reducing Oxidative Stress and/or Side Effects Occurring During Cancer Chemotherapy or Improving Nutritional Status During Cancer Chemotherapy - Provided is a composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving a nutritional status during cancer chemotherapy. The composition is one for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy and comprises the following components (a) to (f): (a) an antioxidant agent; (b) at least one component selected from the group consisting of vitamin B | 2010-11-18 |
20100291058 | Sealants for Skin and Other Tissues - The present invention relates to sealants for skin and other tissues. The sealants include an electroprocessed material. The sealants may contain more than one electroprocessed materials and may contain additional substances. The invention further relates to methods of making and using such sealants. | 2010-11-18 |
20100291059 | PHARMACEUTICAL COMPOSITION FOR ENZYME REPLACEMENT THERAPY - The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 2010-11-18 |
20100291060 | SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A - The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. | 2010-11-18 |
20100291061 | PROCESS FOR MAKING OLIGOPEPTIDES - There is described a method of synthesising a family of oligopeptides of predetermined amino acid sequence, which together make up from 7 amino acids to the complete amino acid sequence of a target protein, which comprises: synthesising a nucleic acid construct which codes for a fusion protein composed of overlapping peptides derived from the desired portion of the target protein, interspersed with regions which code for protease cleavage sites, expressing the nucleic acid construct in a suitable expression vector, harvesting the fusion protein corresponding to the nucleic acid sequence, and digesting the fusion protein with a protease selective for the cleavage sites to generate the oligopeptides. The oligopeptides may be generated in vitro or in vitro and may be used as vaccines against viral infections and in epitope mapping. | 2010-11-18 |
20100291062 | Antimicrobial Composition - A complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Aerosil is used as a siliceous sorbent, and seratiopeptidase as a drug. | 2010-11-18 |
20100291063 | PROTEASE INHIBITION - The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment. | 2010-11-18 |
20100291064 | Compounds and Methods for the Treatment of Vascular Disease - The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction. | 2010-11-18 |
20100291065 | Compositions for Protein Delivery and Methods of Use Thereof - Compositions and methods for the delivery of a protein of interest are provided. | 2010-11-18 |
20100291066 | DONOR SPECIFIC ANTIBODY LIBRARIES - The present application concerns donor-specific antibody libraries derived from a patient donor who has suffered from, or is suffering from one or more diseases discussed herein. The present application also concerns the method of making and using the donor-specific antibodies. The present application further concerns the neutralizing antibodies obtained from the donor-specific antibody libraries and the methods of using these antibodies for the prevention/treatment of human disease. | 2010-11-18 |
20100291067 | Methods And Compositions Relating to Viral Latency - Disclosed are compositions and methods that relate generally to viruses, and more particularly to the agents and their identification and use of anti-HIV agents which cause latently infected cells to reactivate. | 2010-11-18 |
20100291068 | NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided. | 2010-11-18 |
20100291069 | METHODS OF TREATING A DIABETIC EMBRYOPATHY - Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy. | 2010-11-18 |
20100291070 | TYPE III SECRETION SYSTEM COMPONENT PROTEIN PA1698 OF PSEUDOMONAS AERUGINOSA - An object is to provide an antibody and a vaccine composition which have an ability to practically prevent or treat a | 2010-11-18 |
20100291071 | Antibody Specific Binding to A-Beta Oligomer and the Use - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2010-11-18 |
20100291072 | ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION RATES - Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds. | 2010-11-18 |
20100291073 | METHODS OF REDUCING EOSINOPHIL LEVELS - The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e g, esophagus, stomach, small intestine and colon), or lung. | 2010-11-18 |
20100291074 | CYCLOPHILIN D-AMYLOID BETA INTERACTION POTENTIATES MITOCHONDRIAL DYSFUNCTION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE - The present invention is directed to methods for treating or preventing Alzheimer's disease by administering therapeutically effective amounts of an agent that reduces Cyclophilin D expression in a patient, or that reduce Cyclophilin D activity or its ability to form a complex with Amyloid beta. Such agents include antisense nucleotides and small interfering RNAs, antibodies that selectively bind to Cyclophilin D, and cyclosporine A and D. | 2010-11-18 |
20100291075 | Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies - The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species. | 2010-11-18 |
20100291076 | ANTIBODIES SPECIFIC FOR DKK-1 AND THEIR USES - The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1 | 2010-11-18 |
20100291077 | Methods and Compositions for Modulating ERBB2 Activity - Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system. | 2010-11-18 |
20100291078 | Proteinaceous binding molecules comprising purification tags or inert variable domains - The present invention provides proteinaceous binding molecules, in particular antibodies, having at least two variable domains. One variable domain binds to a target molecule of interest. At least one other variable domain comprises a purification tag suitable for purification of said proteinaceous binding molecule. The purification tag enables the convenient purification of the proteinaceous binding molecule with monovalent binding properties against the target molecule. | 2010-11-18 |
20100291079 | Heterodimeric Follicle Stimulating Hormone-Fc (FSH-Fc) Fusion Proteins for the Treatment of Infertility - The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (αFSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (βFSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH. | 2010-11-18 |